Skip to content

RCT of effect of cotrimoxazole on the health of HIV-exposed unifected infants

Randomized controlled trial testing the effect of cotrimoxazole prophylaxis on morbidity and mortality outcomes in breastfed HIV-exposed uninfected infants

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR201311000621110
Enrollment
1298
Registered
2013-08-21
Start date
2013-09-16
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/AIDS

Interventions

CTX prophylaxis
No CTX prophylaxis

Sponsors

University of KwaZulu Natal
Lead Sponsor
eThekwini Municipality Health Unit
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Infant born to a woman with confirmed HIV infection; Written informed consent to enroll infant into study obtained from mother; Infant age 6 weeks (between day 35-49) at study entry; Infant should be breastfeeding at time of screening and should be planning to breastfeed for at least 6 months; HIV-negative from a screening test performed prior to study entry; Mother (or infant) should be receiving PMTCT regimen or mother should be receiving lifelong ART; Singleton birth; Birth weight >2000g; Infant has not had any illness and has not received prior antibiotics or traditional medications;

Exclusion criteria

Exclusion criteria: Indeterminate HIV test result at screening; Receipt of antibiotics or traditional medications prior to study entry; A known requirement for CTX prophylaxis prior to study entry; A known contra-indication for CTX prophylaxis prior to study entry; Infants with any major serious illness (eg., heart, liver, kidney disease) or congenital malformation;

Design outcomes

Primary

MeasureTime frame
To compare incidence of grade 3 and 4 common childhood illnesses or all-cause mortality through 54 weeks of age in HEUs receiving CTX or no CTX.

Secondary

MeasureTime frame
To compare incidence of grade 3 and 4 diarrheal events through 54 weeks of age in group receiving CTX vs no CTX;To compare incidence of grade 3 and 4 pneumonia events through 54 weeks of age in group receiving CTX vs no CTX;To compare the incidence of growth faltering events through 54 weeks of age in the group recieving CTX vs no CTX;To compare concentrations of LPS and 16s ribosomal RNA in infant plasma in a subsample of infants receiving CTX vs no CTX;To compare characteristics of gut microbiota in a subsample of infants receiving CTX vs no CTX

Countries

South Africa

Contacts

Public ContactEshia Moodley-Govender

Postdoctoral Fellow

Moodleye@ukzn.ac.za0312604489

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026